财务数据关键指标变化：收入和利润 - 截至2025年11月29日的十三周净销售额为3.402亿美元，同比下降0.3%[92][96] - 截至2025年11月29日的十三周毛利润为1.099亿美元，同比下降15.8%[98] - 截至2025年11月29日的十三周营业利润为3758.4万美元，占净销售额的11.0%[96] - 截至2025年11月29日的十三周净利润为2526.9万美元，同比下降1285.3万美元[96][104] - 公司净收入为2526.9万美元，相比去年同期的3812.2万美元下降33.7%[108] - 调整后EBITDA为5562.4万美元，占净销售额的16.4%[96] - 调整后EBITDA为5562.4万美元，同比下降1444.4万美元或20.6%，主要受毛利下降驱动[105][108] 财务数据关键指标变化：成本和费用 - 截至2025年11月29日的十三周毛利率为32.3%，同比下降590个基点[93][96][98] - 销售成本为2.30298亿美元，同比增长9.3%[96][97] - 销售与营销费用为2967.7万美元，同比下降10.1%[96][99] - 一般及行政费用为3800.6万美元，同比下降0.2%[96][99] - 利息支出为428.6万美元，同比减少357.5万美元或45.5%[108] - 折旧及摊销费用为620.5万美元，同比增加115.8万美元或22.9%[108] 现金流表现 - 经营活动产生的现金流量净额为5009.4万美元，同比增加1810万美元或56.5%[129] - 投资活动净现金使用额为210万美元，较上年同期70万美元增长200%[130] - 2025财年十三周投资活动现金主要用于购买物业和设备，金额为210万美元[130] - 2024财年同期投资活动现金使用包括30万美元购买物业和设备及40万美元投资无形资产和其他资产[130] - 融资活动净现金提供额为4760万美元，上年同期为净现金使用4230万美元[131] - 2025财年十三周融资活动现金主要来自发行长期债务所得1.5亿美元及期权行权所得110万美元[131] - 2025财年十三周融资活动现金使用包括9960万美元回购普通股及120万美元支付股权激励相关税费[131] - 2024财年同期融资活动现金使用包括5000万美元偿还定期贷款本金及230万美元支付股权激励相关税费[131] - 2024财年同期融资活动现金部分被期权行权所得1000万美元抵消[131] 资本结构与融资活动 - 截至2025年11月29日，公司定期贷款未偿还余额增至4亿美元[102] - 期末定期贷款（Term Facility）未偿还本金余额为4亿美元，到期日为2030年3月[124] - 公司遵守了所有债务契约，总净杠杆率未超过6.00:1.00的限制[123] 股东回报与资本配置 - 公司在截至2025年11月29日的十三周内，以平均每股19.99美元的价格回购了4,983,514股普通股，总金额约9960万美元[125] - 股票回购计划总额增至3亿美元，截至2025年11月29日仍有约7100万美元的授权回购额度[125][126] 其他财务数据 - 截至2025年11月29日，公司现金及现金等价物为1.941亿美元[110] 其他重要内容 - 公司在截至2025年11月29日的十三周内市场风险敞口无重大变化[134]

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 7, 2026 SELLAS Life Sciences Group, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33958 20-8099512 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Identification No.) 7 Times Square, Suite 2503 New York, ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CORMEDIX INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-34673 20-5894890 (State or Other Jurisdiction (Commission File Number) (IRS Employer of Incorporation) Identification No.) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 300 Connell Drive, Suite 4200 Berkeley Heights, New Jersey 07922 (Address of Principal Executive Offices) (Zip Code) Date of Report (Date of ...

财务数据关键指标变化（现金及等价物） - 现金及等价物同比减少约9560万美元（约13.5%）[4] 财务数据关键指标变化（现金余额） - 截至2025年12月31日，公司现金、现金等价物及有价债务证券的初步估计约为6.11亿美元[4] - 截至2024年12月31日，公司现金、现金等价物及有价债务证券为7.067亿美元[4] 管理层讨论和指引（现金流预测） - 根据当前运营计划，公司预计现有现金可支持研发项目及运营至2028年[4] 其他没有覆盖的重要内容（数据说明与风险） - 该初步估计并非公司2025财年财务业绩的完整报表，且未经独立审计师审计、审阅或编制[5] - 实际现金及等价物可能因年终结算和审计程序完成而与初步估计存在差异[5]

Exhibit 10.1 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark "[***]". LOAN AND SECURITY AGREEMENT Dated as of January 7, 2026 among and any Person from time to time party hereto as a lender (in such capacity, with Avenue 2, a "Lender" and collectively, the "Lenders") LOAN AND SECURITY A ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2026 Personalis, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38943 27-5411038 (State or Other Jurisdiction of Incorporation) 6600 Dumbarton Circle Fremont, California 94555 (Address of Principal Executive Offices) (Zip Code) (Commission File Number) (IRS ...

AXIL Brands, Inc. Reports Second Quarter Fiscal Year 2026 Financial Results LOS ANGELES, January 8, 2026 (GLOBE NEWSWIRE) – AXIL Brands, Inc. ("AXIL," "we," "us," "our," or the "Company") (NYSE American: AXIL), an emerging global consumer products company for AXIL® hearing protection and enhancement products and Reviv3® hair and skin care products, today announced financial and operational results for the second quarter ended November 30, 2025 (2Q26). Financial Highlights (Quarter Ended November 30, 2025) R ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to __________________ Commission File Number: 001-11038 ____________________ NORTHERN TECHNOLOGIES INTERNAT ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to _____________ Commission File Number: 001-41958 AXIL Brands, Inc. (Exact Name of Registrant as Specified in Its Charter) | Delaware | 47-4125218 | | -- ...

FORM 8-K Washington, D.C. 20549 CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 7, 2026 Frontier Group Holdings, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation) UNITED STATES SECURITIES AND EXCHANGE COMMISSION ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b ...